Abstract: Disclosed herein are kits and methods for assessing the risk of poor reading performance in an individual by detecting and identifying single nucleotide polymorphisms in chromosome 19, e.g. in the KIAA0355 (GARRE1) gene. Also disclosed herein are risk alleles in chromosome 19 that are associated with a latent measure for reading ability.
Type:
Application
Filed:
October 8, 2020
Publication date:
January 18, 2024
Applicants:
Yale University, Brock University
Inventors:
Jeffrey R. Gruen, Andrew Adams, Dongnhu Truong, Jan Frijters, Joan Bosson-Heenan
Abstract: The present disclosure relates to self-healing siloxane elastomers. In particular, the present disclosure relates to self-healing siloxane elastomers comprising at least one siloxane polymer reversibly crosslinked to a second siloxane oligomer or polymer.
Abstract: The present application relates to methods and compounds for enhancing contrast in magnetic resonance imaging. The methods comprise administering compounds of Formula I(a) or I(b) to a subject and obtaining a magnetic resonance image of the subject. The present application also relates to methods of preparing compounds of the Formula I(a) as well as intermediate compounds used in such a method of preparation.
Abstract: Disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof as an adjuvant for the preparation of an oral vaccine. Further disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof for enhancing the immune response to an orally administered vaccine.
Type:
Grant
Filed:
September 18, 2018
Date of Patent:
July 23, 2019
Assignees:
Brock University, National Research Council of Canada
Inventors:
Hongbin Yan, Wangxue Chen, Rhonda Kuo Lee
Abstract: Disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof as an adjuvant for the preparation of an oral vaccine. Further disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof for enhancing the immune response to an orally administered vaccine.
Type:
Grant
Filed:
November 18, 2014
Date of Patent:
October 9, 2018
Assignees:
Brock University, National Research Council of Canada
Inventors:
Hongbin Yan, Wangxue Chen, Rhonda Kuo Lee
Abstract: The present application is directed to an efficient conversion of C-14 hydroxylated morphine alkaloids to various morphine analogs, such as naltrexone, naloxone and nalbuphone. One feature of this process is an intramolecular functional group transfer from the C-14 hydroxyl to the N-17 nitrogen atom following a palladium-catalyzed N-demethylation.
Abstract: The present application relates to methods and compounds for enhancing contrast in magnetic resonance imaging. The methods comprise administering compounds of Formula I(a) or I(b) to a subject and obtaining a magnetic resonance image of the subject. The present application also relates to methods of preparing compounds of the Formula I(a) as well as intermediate compounds used in such a method of preparation.
Abstract: The present application discloses siloxane-containing hybrid materials. For example, the present application discloses siloxane-containing hybrid materials comprising cyclic siloxanes or polyhedral siloxanes such as polymeric siloxane-containing hybrid materials comprising cyclic siloxanes or polyhedral siloxanes, methods for preparing such siloxane-containing hybrid materials, the use of such siloxane-containing hybrid materials for coating a substrate, coatings comprising the polymeric siloxane-containing hybrid materials, composites comprising a film of the polymeric siloxane-containing material coated on a substrate and compounds which are useful in preparing the siloxane-containing hybrid materials.
Abstract: Disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof as an adjuvant for the preparation of an oral vaccine. Further disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof for enhancing the immune response to an orally administered vaccine.
Type:
Application
Filed:
November 18, 2014
Publication date:
October 6, 2016
Applicants:
BROCK UNIVERSITY, NATIONAL RESEARCH COUNCIL CANADA
Inventors:
Hongbin YAN, Wangxue CHEN, Rhonda KUO LEE
Abstract: The present application is directed to novel imidazole-substituted fatty acids that have been functionalized with an alkyl triphenylphosphonium group, compositions comprising these compounds and their use as inhibitors of cytochrome c peroxidase, in particular for the treatment and prevention of apoptosis.
Type:
Grant
Filed:
November 13, 2012
Date of Patent:
June 14, 2016
Assignees:
University of Pittsburgh—Of the Commonwealth System of Higher Education, Brock University
Inventors:
Jeffrey Atkinson, Jeffrey Stuart, Valarian E. Kagan, Detcho A. Stoyanovsky, Michael W. Epperly, Joel S. Greenberger, Hülya Bayîr
Abstract: The present invention provides a method for the N-demethylation and N-functionalization of an N-methylated heterocycle such as a morphine alkaloid or tropane alkaloid. The method comprises reacting the heterocycle with an functionalization agent in the presence of a transition metal catalyst in air or in the presence of an oxidant.
Type:
Grant
Filed:
January 30, 2015
Date of Patent:
May 17, 2016
Assignee:
Brock University
Inventors:
Tomas Hudlicky, Robert James Carroll, Hannes Leisch, Ales Machara, Lukas Werner, Mary Ann Endoma-Arias
Abstract: The present application relates to processes for the preparation of morphine compounds utilizing a novel intramolecular [4+2] cycloaddition reaction.
Abstract: The present application relates to processes for the preparation of morphine compounds utilizing a novel intramolecular [4+2] cycloaddition reaction.
Abstract: The present application is directed to an efficient conversion of C-14 hydroxylated morphine alkaloids to various morphine analogs, such as naltrexone, naloxone and nalbuphone. One feature of this process is an intramolecular functional group transfer from the C-14 hydroxyl to the N-17 nitrogen atom following a palladium-catalyzed N-demethylation.
Abstract: A high-yielding method for the N-demethylation of oxycodone- and oxymorphone-N-oxides by the reaction of these compounds with cyclodehydration reagents has been performed. This method has been utilized to improve the synthesis of various morphine analogs, such as naltrexone, nalbuphone and naloxone.
Type:
Grant
Filed:
January 7, 2015
Date of Patent:
June 2, 2015
Assignee:
Brock University
Inventors:
Tomas Hudlicky, Lukas Werner, Ales Machara, Martina Wernerova, Mary Ann Endoma-Arias
Abstract: The oxazolidine derived from the reaction of oxymorphone with the Burgess reagent, temporarily protected at O-3 and C-6, reacts with Grignard or other suitable metallic or organometallic reagents to directly provide, for example, A/-allyl, A/-methylcyclopropyl and /V-methylcyclobutyl derivatives that are further converted into naltrexone, naloxone, nalbuphone and nalbuphine in excellent yields. These morphine analogs can be prepared from the oxazolidine in a one-pot synthesis.
Abstract: The present invention provides a method for the N-demethylation and N-functionalization of an N-methylated heterocycle such as a morphine alkaloid or tropane alkaloid. The method comprises reacting the heterocycle with an functionalization agent in the presence of a transition metal catalyst in air or in the presence of an oxidant.
Type:
Grant
Filed:
July 8, 2011
Date of Patent:
February 24, 2015
Assignee:
Brock University
Inventors:
Tomas Hudlicky, Robert James Carroll, Hannes Leisch, Ales Machara, Lukas Werner, Mary Ann Endoma-Arias
Abstract: A high-yielding method for the N-demethylation of oxycodone- and oxymorphone-N-oxides by the reaction of these compounds with cyclodehydration reagents has been performed. This method has been utilized to improve the synthesis of various morphine analogs, such as naltrexone, nalbuphone and naloxone.
Type:
Grant
Filed:
May 2, 2012
Date of Patent:
February 17, 2015
Assignee:
Brock University
Inventors:
Tomas Hudlicky, Lukas Werner, Ales Machara, Martina Wernerova, Mary Ann Endoma-Arias
Abstract: The present application is directed to an efficient conversion of C-14 hydroxylated morphine alkaloids to various morphine analogs, such as naltrexone, naloxone and nalbuphone. One feature of this process is an intramolecular functional group transfer from the C-14 hydroxyl to the N-17 nitrogen atom following a palladium-catalyzed N-demethylation.
Abstract: The oxazolidine derived from the reaction of oxymorphone with the Burgess reagent, temporarily protected at 0-3 and C-6, reacts with Grignard or other suitable metallic or organometallic reagents to directly provide, for example, A/-allyl, A/-methylcyclopropyl and /V-methylcyclobutyl derivatives that are further converted into naltrexone, naloxone, nalbuphone and nalbuphine in excellent yields. These morphine analogs can be prepared from the oxazolidine in a one-pot synthesis.